Rein Therapeutics Inc (RNTX)
Healthcare
Biotechnology
0.74 $
-3.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Rein Therapeutics Inc (RNTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 83.6% of the shares are freely tradable; institutional investors hold 24.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
24.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
5.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
83.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
0.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
86Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Voss Capital LLC | 5.13 | 4,388,362 | +3.4 | 03/31/2026 |
| BIOS CAPITAL MANAGEMENT, LP | 2.32 | 1,982,375 | +17.2 | 03/31/2026 |
| Vanguard Group Inc | 1.36 | 1,165,807 | -0.2 | 12/31/2025 |
| Vanguard Capital Management, LLC | 1.17 | 998,521 | +0.0 | 03/31/2026 |
| University Of Texas Investment Mgmt Co | 0.60 | 511,610 | +0.0 | 03/31/2026 |
| Cable Car Capital LLC | 0.49 | 420,000 | +0.0 | 12/31/2025 |
| Prosight Management, LP | 0.48 | 411,600 | -7.0 | 03/31/2026 |
| Sigma Planning Corp | 0.41 | 348,677 | +41.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.40 | 344,690 | +21.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 0.86 | 734,417 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.